mersana therapeutics inc. - MRSN
MRSN
Close Chg Chg %
28.73 -0.08 -0.28%
Closed Market
28.65
-0.08 (0.28%)
Volume: 302.78K
Last Updated:
Dec 30, 2025, 4:00 PM EDT
Company Overview: mersana therapeutics inc. - MRSN
MRSN Key Data
| Open $28.56 | Day Range 28.11 - 28.98 |
| 52 Week Range 5.21 - 37.88 | Market Cap $143.61M |
| Shares Outstanding 5.00M | Public Float 3.89M |
| Beta 0.44 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$14.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 72.06K |
MRSN Performance
| 1 Week | -1.46% | ||
| 1 Month | 4.45% | ||
| 3 Months | 246.01% | ||
| 1 Year | -19.86% | ||
| 5 Years | -95.69% |
MRSN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About mersana therapeutics inc. - MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
MRSN At a Glance
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, Massachusetts 02139
| Phone | 1-617-498-0020 | Revenue | 40.50M | |
| Industry | Biotechnology | Net Income | -69,192,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 9.882% | |
| Fiscal Year-end | 12 / 2025 | Employees | 102 | |
| View SEC Filings |
MRSN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.327 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.966 |
| Enterprise Value to Sales | 1.71 |
| Total Debt to Enterprise Value | 0.414 |
MRSN Efficiency
| Revenue/Employee | 397,029.412 |
| Income Per Employee | -678,352.941 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.218 |
MRSN Liquidity
| Current Ratio | 2.192 |
| Quick Ratio | 2.192 |
| Cash Ratio | 2.155 |
MRSN Profitability
| Gross Margin | 95.98 |
| Operating Margin | -181.09 |
| Pretax Margin | -169.825 |
| Net Margin | -170.857 |
| Return on Assets | -37.328 |
| Return on Equity | -505.143 |
| Return on Total Capital | -361.448 |
| Return on Invested Capital | -203.518 |
MRSN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 149.674 |
| Total Debt to Total Assets | 19.806 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 63.992 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Mersana Therapeutics Inc. - MRSN
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 43.00K | 26.58M | 36.85M | 40.50M | |
Sales Growth
| -94.81% | +61,716.28% | +38.65% | +9.88% | |
Cost of Goods Sold (COGS) incl D&A
| - | 927.00K | 1.52M | 1.63M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 855.00K | 927.00K | 1.52M | 1.63M | |
Depreciation
| 855.00K | 927.00K | 1.52M | 1.63M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +63.65% | +7.32% | - |
Gross Income
| - | 25.65M | 35.34M | 38.87M | |
Gross Income Growth
| - | - | +37.75% | +9.99% | - |
Gross Profit Margin
| - | +96.51% | +95.88% | +95.98% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 168.05M | 229.42M | 206.29M | 112.20M | |
Research & Development
| 131.16M | 172.46M | 148.27M | 73.02M | |
Other SG&A
| 36.89M | 56.96M | 58.03M | 39.19M | |
SGA Growth
| +91.12% | +36.52% | -10.08% | -45.61% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 8.71M | - |
EBIT after Unusual Expense
| (168.86M) | (203.77M) | (179.67M) | (73.34M) | |
Non Operating Income/Expense
| 65.00K | 2.88M | 12.07M | 8.44M | |
Non-Operating Interest Income
| 65.00K | 2.88M | 12.07M | 8.44M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.27M | 3.33M | 4.07M | 3.87M | |
Interest Expense Growth
| +252.92% | +162.67% | +22.39% | -4.89% | |
Gross Interest Expense
| 1.27M | 3.33M | 4.07M | 3.87M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (170.06M) | (204.21M) | (171.67M) | (68.77M) | |
Pretax Income Growth
| -93.15% | -20.08% | +15.94% | +59.94% | |
Pretax Margin
| -395,488.37% | -768.26% | -465.80% | -169.82% | |
Income Tax
| - | - | - | 418.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (170.06M) | (204.21M) | (171.67M) | (69.19M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (170.06M) | (204.21M) | (171.67M) | (69.19M) | |
Net Income Growth
| -93.15% | -20.08% | +15.94% | +59.69% | |
Net Margin Growth
| -395,488.37% | -768.26% | -465.80% | -170.86% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (170.06M) | (204.21M) | (171.67M) | (69.19M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (170.06M) | (204.21M) | (171.67M) | (69.19M) | |
EPS (Basic)
| -60.2358 | -54.5122 | -36.9618 | -14.1162 | |
EPS (Basic) Growth
| -4,106.41% | +9.50% | +32.20% | +61.81% | |
Basic Shares Outstanding
| 2.82M | 3.75M | 4.64M | 4.90M | |
EPS (Diluted)
| -60.2358 | -54.5122 | -36.9618 | -14.1162 | |
EPS (Diluted) Growth
| -4,106.41% | +9.50% | +32.20% | +61.81% | |
Diluted Shares Outstanding
| 2.82M | 3.75M | 4.64M | 4.90M | |
EBITDA
| (168.00M) | (202.84M) | (169.44M) | (71.71M) | |
EBITDA Growth
| -92.89% | -20.74% | +16.47% | +57.68% | |
EBITDA Margin
| -390,704.65% | -763.10% | -459.75% | -177.07% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 32.667 | |
| Number of Ratings | 8 | Current Quarters Estimate | -2.951 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -9.594 | |
| Last Quarter’s Earnings | -3.17 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -7.136 | Next Fiscal Year Estimate | -9.015 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 7 | 4 |
| Mean Estimate | -2.95 | -2.35 | -9.59 | -9.02 |
| High Estimates | -1.24 | -1.23 | -0.71 | -2.78 |
| Low Estimate | -4.11 | -3.47 | -17.02 | -14.87 |
| Coefficient of Variance | -51.18 | -47.55 | -59.43 | -55.81 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 8 | 8 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Buy |
SEC Filings for Mersana Therapeutics Inc. - MRSN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Mersana Therapeutics Inc. - MRSN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 17, 2025 | Anna Protopapas Director | 161,619 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Anna Protopapas Director | 155,428 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.63 per share | 97,919.64 |
| Jan 17, 2025 | Anna Protopapas Director | 16,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Timothy B. Lowinger SVP, Chief Sci.&Tech. Officer | 247,724 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Timothy B. Lowinger SVP, Chief Sci.&Tech. Officer | 245,930 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.63 per share | 154,935.90 |
| Jan 17, 2025 | Timothy B. Lowinger SVP, Chief Sci.&Tech. Officer | 4,791 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Alejandra Veronica Carvajal SVP, Chief Legal Officer | 71,844 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Alejandra Veronica Carvajal SVP, Chief Legal Officer | 70,892 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.63 per share | 44,661.96 |
| Jan 17, 2025 | Alejandra Veronica Carvajal SVP, Chief Legal Officer | 2,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Brian DeSchuytner SVP, COO & CFO | 111,361 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Brian DeSchuytner SVP, COO & CFO | 109,030 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.63 per share | 68,688.90 |
| Jan 17, 2025 | Brian DeSchuytner SVP, COO & CFO | 6,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Ashish Mandelia VP, Chief Accounting Officer | 54,179 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 17, 2025 | Ashish Mandelia VP, Chief Accounting Officer | 52,388 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.63 per share | 33,004.44 |
| Jan 17, 2025 | Ashish Mandelia VP, Chief Accounting Officer | 4,783 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Lawrence M. Alleva Director | 12,521 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |